On CytoDyn's (CYDY) upcoming earnings call, investor focus will be on the updates related to its CCR5 antagonist candidate, leronlimab, which is being developed for multiple therapeutic indications.
Some BioLife Solutions, Inc. (NASDAQ:BLFS) shareholders are probably rather concerned to see the share price fall 42...
NEW YORK, NY / ACCESSWIRE / March 11, 2020 / BioLife Solutions, Inc. (NASDAQ:BLFS) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 11, 2020 at 4:30 ...
In 2006 Mike Rice was appointed CEO of BioLife Solutions, Inc. (NASDAQ:BLFS). First, this article will compare CEO...
Q4 2019 Biolife Solutions Inc Earnings Call
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced preliminary revenue for the first quarter of 2020.
Now I'd like to turn the call over to Mike Rice, President and CEO of BioLife. For the last month or so of the quarter, we had our team members either working from home, part of an essential reduced on site workforce who are not working through all the transition to get our customer support teams up and running remotely, we stayed in close contact with our customers and shipped more media products than in any other period and BioLife history. While it's clear that cell and gene therapy clinical trials have been significantly affected by the reallocation of hospital beds to COVID patients, our customers are planning for success and clearly demonstrated through their order volume that our media products are considered mission critical to their cell and gene therapy manufacturing workflow.
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced that the Company's first quarter 2020 financial results will be released after market close on Thursday, May 14th, 2020, and that the Company will host a conference call and live webcast at 4:30 p.m. ET (1:30 p.m. PT) that afternoon. Management will provide an overview of the Company's financial results and a general business update.
BioLife Solutions, Inc. (NASDAQ:BLFS), which is in the medical equipment business, and is based in United States, saw...
Anyone researching BioLife Solutions, Inc. (NASDAQ:BLFS) might want to consider the historical volatility of the share...
Q3 2019 Biolife Solutions Inc Earnings Call
Of Washington's public companies, 21 at least doubled their stock price from Dec. 27, 2010 to Dec. 26, 2019.
Unfortunately for some shareholders, the BioLife Solutions (NASDAQ:BLFS) share price has dived 36% in the last thirty...
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today reported financial results and operational highlights for the fourth quarter and full year ended December 31, 2019.
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced the dates for several key events:
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced financial results for the three months ended March 31, 2020.
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced the promotion of Marcus Schulz to the position of Vice President, Global Sales. He is replacing Jim Mathers, Chief Revenue Officer, who is retiring on June 30, 2020.
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
BioLife Solutions (BLFS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
BioLife Solutions shares opened higher before moving sharply lower Thursday despite a higher analyst price target.